| Literature DB >> 21450549 |
Ruthann A Rudel1, Janet M Gray, Connie L Engel, Teresa W Rawsthorne, Robin E Dodson, Janet M Ackerman, Jeanne Rizzo, Janet L Nudelman, Julia Green Brody.
Abstract
BACKGROUND: Bisphenol A (BPA) and bis(2-ethylhexyl) phthalate (DEHP) are high-production-volume chemicals used in plastics and resins for food packaging. They have been associated with endocrine disruption in animals and in some human studies. Human exposure sources have been estimated, but the relative contribution of dietary exposure to total intake has not been studied empirically.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21450549 PMCID: PMC3223004 DOI: 10.1289/ehp.1003170
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Characteristics of the 20 participants.
| Table 1. Characteristics of the 20 participants. | |
| Characteristic | |
| Age (years) | |
| < 6 | 3 (15) |
| 6 to < 12 | 7 (35) |
| 12 to < 20 | 0 (0) |
| 20 to < 40 | 4 (20) |
| 40 to < 60 | 6 (30) |
| ≥ 60 | 0 (0) |
| Ethnicity | |
| White | 14 (70) |
| Hispanic | 1 (5) |
| Asian | 1 (5) |
| Mixed | 4 (20) |
| Sex | |
| Male | 9 (45) |
| Female | 11 (55) |
| Urinary creatinine | |
| Preintervention | |
| < 118.6 mg/dL | 11 (55) |
| > 118.6 mg/dL | 9 (45) |
| During intervention | |
| < 118.6 mg/dL | 11 (55) |
| > 118.6 mg/dL | 9 (45) |
| Postintervention | |
| < 118.6 mg/dL | 13 (65) |
| > 118.6 mg/dL | 7 (35) |
Figure 1Intervention study design (n = 20 individuals from five families). Each participant provided a total of six urine samples (arrows; two per phase). Paired samples collected from each individual during each phase were combined for analysis.
Figure 2Box plots showing the distribution of urinary levels of BPA and phthalate metabolites in preintervention (Pre), intervention, and postintervention (Post) samples. Boxes represent values between the 25th and 75th percentiles; black lines inside boxes indicate medians; whiskers indicate the range of nonoutlier data points (using Tukey’s definition of outliers); and circles represent outliers. The fresh food intervention was associated with significant reductions in urinary excretion of BPA (A) and metabolites of DEHP [MEHP (B), MOHP (C), and MEHHP (D)]. No significant changes were observed in the other phthalate metabolites analyzed, although there was a small reduction in the DBP metabolite MBUP (F); concentrations of MEP (E), MBZP (G), and MMEP (H) showed little change. Compared with the 2007–2008 NHANES sample of 2,604 individuals ≥ 6 years of age (CDC 2009), the preintervention medians and 95th percentile estimates for adults and children combined were higher for BPA (A), DEHP metabolites (B–D), MBUP (F), and MMEP (H), much lower for MEP (E), and similar for MBZP (G). The NHANES median for MMEP was < LOD of 1.1 ng/mL, and the NHANES 95th percentile for MEP was 2,140 ng/mL. *p < 0.05, and **p < 0.005 for reductions or increases between intervention phases as determined by p-value for slope in the mixed-effects model.
Preintervention concentrations of urinary analytes.
| Table 2. Preintervention concentrations of urinary analytes. | ||||||||||||||||||||||
| Adults ( | NHANES adult median | Children ( | NHANES child median | Study combined median | NHANES overall median | |||||||||||||||||
| Analyte | MRL | Min | Median | Max | Min | Median | Max | |||||||||||||||
| Creatinine (mg/dL) | 58 | 150 | 220 | 119–128.8 | 33 | 68 | 160 | 98.09 | 100 | 118.6 | ||||||||||||
| BPA (ng/mL) | 0.25 | 1.0 | 4.9 | 11 | 2 | 1.2 | 2.6 | 16 | 2.4 | 3.4 | 2.1 | |||||||||||
| MEHP (ng/mL) | 1 | 3.3 | 7.4 | 190 | 2.1 | 2.1 | 3.9 | 15 | 2.2 | 4.5 | 2.2 | |||||||||||
| MEOHP (ng/mL) | 1 | 9.5 | 24 | 630 | 10.7 | 11 | 16 | 66 | 16.5 | 17 | 11.4 | |||||||||||
| MEHHP (ng/mL) | 1 | 22 | 50 | 1,400 | 19.6 | 15 | 35 | 150 | 27 | 42 | 20.7 | |||||||||||
| MEP (ng/mL) | 7 | 32 | 73 | 340 | 128 | 6.7 | 25 | 39 | 68.7 | 34 | 124 | |||||||||||
| MBUP | 1 | 18 | 30 | 160 | 26 | 34 | 46 | 160 | 40.1 | 39 | 28 | |||||||||||
| MBZP (ng/mL) | 1 | 2.9 | 8.0 | 32 | 9.9 | 3.9 | 12 | 82 | 24.2 | 8.3 | 11.7 | |||||||||||
| MMEP (ng/mL) | 5 | < MRL | 8.1 | 34 | < 1.1 | 5.7 | 15 | 38 | 1.2 | 13 | < 1.1 | |||||||||||
| Abbreviations: Max, maximum; Min, minimum. | ||||||||||||||||||||||
Mixed-effects model results for multilevel spline model.
| Table 3. Mixed-effects model results for multilevel spline model. | ||||||
| Analyte | Intervention variable | Percent change in GM per time period (ng/mL) | 95% CI for slope estimate | |||
| BPA | Pre vs. during | –66% (3.7 vs. 1.2) | –1.6 to –0.55** | |||
| During vs. post | 202% (1.2 vs. 3.8) | 0.61 to 1.6** | ||||
| MEHP | Pre vs. during | –53% (7.1 vs. 3.4) | –1.2 to –0.16* | |||
| During vs. post | 21% (3.4 vs. 4.1) | –0.32 to 0.74 | ||||
| MEOHP | Pre vs. during | –55% (27 vs. 12) | –1.2 to –0.2* | |||
| During vs. post | 16% (12 vs. 14) | –0.35 to 0.69 | ||||
| MEHHP | Pre vs. during | –56% (57 vs. 25) | –1.3 to –0.25* | |||
| During vs. post | 22% (25 vs. 31) | –0.3 to 0.72 | ||||
| MEP | Pre vs. during | 23% (41 vs. 50) | –0.059 to 0.7 | |||
| During vs. post | 7% (50 vs. 53) | –0.28 to 0.47 | ||||
| MBUP | Pre vs. during | –25% (43 vs. 32) | –0.44 to 0.043 | |||
| During vs. post | 11% (32 vs. 35) | –0.12 to 0.36 | ||||
| MBZP | Pre vs. during | –12% (12 vs. 10) | –0.38 to 0.36 | |||
| During vs. post | 13% (10 vs. 11) | –0.22 to 0.51 | ||||
| MMEP | Pre vs. during | –4% (12 vs. 12) | –0.28 to 0.32 | |||
| During vs. post | –19% (12 vs. 9.3) | –0.5 to 0.091 | ||||
| Abbreviations: CI, confidence interval; Post, postintervention; Pre, Preintervention. | ||||||